Patient leaflet - LEVETIRACETAM 250 MG FILM-COATED TABLETS
Read all of this leaflet carefully before you or your child start taking this medicine because it contains important information for you.
-
- Keep this leaflet. You may need to read it again.
-
- If you have any further questions, ask your doctor or pharmacist.
-
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
-
- If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
The name of your medicine is Levetiracetam 250mg, 500mg, 750mg and 1,000mg Film-
Coated Tablets. In the rest of the leaflet it is called Levetiracetam Tablets.
What is in this leaflet:
-
1. What Levetiracetam Tablets are and what they are used for
-
2. What you need to know before you take Levetiracetam Tablets
-
3. How to take Levetiracetam Tablets
-
4. Possible side effects
-
5. How to store Levetiracetam Tablets
-
6. Contents of the pack and other information
11. What Levetiracetam Tablets are and what they are used for
Levetiracetam is an antiepileptic medicine (a medicine used to treat seizures in epilepsy).
Levetiracetam Tablets are used:
- on their own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy. Epilepsy is a condition where the patients have repeated fits (seizures). Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation). Levetiracetam has been given to you by your doctor to reduce the number of fits.
- as an add-on to other antiepileptic medicines to treat:
o partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age
o myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy
o primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
12. what you need to know before you take levetiracetam tablets if you are allergic to levetiracetam, pyrrolidone derivatives or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
- If you suffer from kidney problems, follow your doctor’s instructions. He/she may decide if your dose should be adjusted.
- If you notice any slowdown in the growth or unexpected puberty development of your child, please contact your doctor.
- A small number of people being treated with anti-epileptics such as Levetiracetam Tablets have had thoughts of harming or killing themselves. If you have any symptoms of depression and/or suicidal ideation, please contact your doctor.
Tell your doctor or pharmacist if any of the following side effects gets serious or last longer than a few days:
- Abnormal thoughts, feeling irritable or reacting more aggressively than usually, or if you or your family and friends notice important changes in mood or behavior.
Children and adolescents
- Levetiracetam Tablets are not indicated in children and adolescents below 16 years on its own (monotherapy).
Other medicines and Levetiracetam Tablets
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Do not take macrogol (a drug used as a laxative) for one hour before and one hour after taking levetiracetam as this may result in a loss of its effect.
Pregnancy and breast-feeding
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your
doctor for advice before taking this medicine. Levetiracetam can be used during pregnancy, only if after
careful assessment it is considered necessary by your doctor.
You should not stop your treatment without discussing it with your doctor. A risk of birth defects for your unborn child cannot be completely excluded.
Breast-feeding is not recommended during treatment.
Driving and using machines
Levetiracetam Tablets may impair your ability to drive or operate any tools or machinery, as they may make you feel sleepy. This is more likely at the beginning of treatment or after an increase in the dose. You should not drive or use machines until it is established that your ability to perform such activities is not affected.
Levetiracetam 750mg Film-Coated Tablets contain sunset yellow FCF aluminium lake (E110) Levetiracetam 750mg Tablets contain sunset yellow FCF aluminium lake (E110), which may cause allergic reactions.
13. how to take levetiracetam tablets
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Take the number of tablets following your doctor’s instructions.
Levetiracetam Tablets must be taken twice a day, once in the morning and once in the evening, at about the same time each day.
Monotherapy
Dose in adults and adolescents (from 16 years of age):
General dose: between 1,000mg and 3,000mg each day.
When you will first start taking Levetiracetam Tablets, your doctor will prescribe you a lower dose (500mg
each day) during 2 weeks before giving you the lowest general dose of 1000mg.
Example: if your daily dose is 1000mg, your reduced starting dose is two tablets of 250mg in the morning
and two tablets of 250mg in the evening.
Add-on therapy
Dose in adults and adolescents (12 to 17 years) weighing 50kg or more:
General dose: between 1,000mg and 3,000mg each day.
Example: if your daily dose is 1000mg, you might take two tablets of 250mg in the morning and two tablets
of 250mg in the evening.
Dose in infants (1 month to 23 months), children (2 to 11 years) and adolescents (12 to
Your doctor will prescribe the most appropriate pharmaceutical form of levetiracetam according to the weight and dose.
Levetiracetam oral solution is a formulation more appropriate to infants and children under the age of 6 years and to children and adolescents (from six to 17 years) weighing less than 50kg and when tablets don’t allow accurate dosage.
Method of administration
Swallow Levetiracetam Tablets with a sufficient quantity of liquid (e.g. a glass of water). You may take Levetiracetam Tablets with or without food. After oral administration the bitter taste of levetiracetam may be experienced.
Duration of treatment
- Levetiracetam Tablets are used as a chronic treatment. You should continue levetiracetam treatment for as long as your doctor has told you.
- Do not stop your treatment without your doctor’s advice as this could increase your seizures.
If you take more Levetiracetam Tablets than you should
The possible side effects of an overdose of Levetiracetam Tablets are sleepiness, agitation, aggression, decrease of alertness, inhibition of breathing and coma.
Contact your doctor if you took more tablets than you should. Your doctor will establish the best possible treatment of overdose.
If you forget to take Levetiracetam Tablets:
Contact your doctor if you have missed one or more doses. Do not take a double dose to make up for a
forgotten tablet.
If you stop taking Levetiracetam Tablets:
If stopping treatment, Levetiracetam Tablets should be discontinued gradually to avoid an increase of seizures. Should your doctor decide to stop your Levetiracetam Tablets treatment, he/she will instruct you about the gradual withdrawal of Levetiracetam Tablets.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
14. possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor immediately, or go to your nearest emergency department, if you experience:
- weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction
- swelling of the face, lips, tongue and throat (Quincke’s oedema)
- flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS])
- symptoms such as low urine volume, tiredness, nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this may be a sign of sudden decrease of kidney function
- a skin rash which may form blisters and look like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme)
- a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome)
- a more severe form of rash causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis)
- signs of serious mental changes or if someone around you notices signs of confusion, somnolence (sleepiness), amnesia (loss of memory), memory impairment (forgetfulness), abnormal behaviour or other neurological signs including involuntary or uncontrolled movements. These could be symptoms of an encephalopathy.
The most frequent reported side effects are nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness. At the beginning of the treatment or at a dose increase, side effects like sleepiness, tiredness and dizziness may be more common. These effects should however decrease over time.
Very common: may affect more than 1 in 10 people
- nasopharyngitis
- somnolence (sleepiness), headache.
Common: may affect up to 1 in 10 people
- anorexia (loss of appetite)
- depression, hostility or aggression, anxiety, insomnia, nervousness or irritability
- convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness),lethargy (lack of energy and enthusiasm), tremor (involuntary trembling);
- vertigo (sensation of rotation)
- cough
- abdominal pain, nausea, dyspepsia (indigestion), diarrhoea, vomiting
- rash
- asthenia/fatigue (tiredness).
Uncommon: may affect up to 1 to 100 people
- decreased number of blood platelets, decreased number of white blood cells;
- weight decrease, weight increase;
- suicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination, anger, confusion, panic attack, emotional instability/mood swings, agitation;
- amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/ataxia (impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration);
- diplopia (double vision), vision blurred;
- elevated/abnormal values in a liver function test;
- hair loss, eczema, pruritus;
- muscle weakness, myalgia (muscle pain);
- injury.
Rare: may affect up to 1 in 1,000 people
- infection
- decreased number of all blood cell types
- severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction], Quincke’s oedema [swelling of the face, lips, tongue and throat])
- decreased blood sodium concentration
- suicide, personality disorders (behavioural problems), thinking abnormal (slow thinking, unable to concentrate)
- delirium;
- encephalopathy (see sub-section “Tell your doctor immediately” for a detailed description of symptoms);
- uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling movements, hyperkinesia (hyperactivity)
- pancreatitis
- liver failure, hepatitis
- sudden decrease in kidney function
- skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals
(Stevens-Johnson syndrome ), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis ).
- rhabdomyolysis (breakdown of muscle tissue) and associated blood creatine phosphokinase increase. Prevalence is significantly higher in Japanese patients when compared to nonJapanese patients.
- limp or difficulty walking
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed
in this leaflet. You can also report side effects directly via the national reporting systems listed below:
United Kingdom:
Yellow Card Scheme
Website:or search for MHRA Yellow Card in the Google Play or Apple App
Store.
Malta:
ADR Reporting
Website:
By reporting side effects you can help provide more information on the safety of this medicine.
5. how to store levetiracetam tablets
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the carton box and blister after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. contents of the pack and other informationthe active substance is levetiracetam. the tablets are available in four strengths: 250mg, 500mg, 750mg and
1,000mg.
The other ingredients of the tablet core are:
Maize starch, croscarmellose sodium, povidone (K-30), colloidal anhydrous silica, purified talc and magnesium stearate.
The tablets are film-coated as follows:
Levetiracetam250mg Tablets – opadry® II blue 85F20694 (polyvinyl alcohol-part.
hydrolysed, titanium dioxide E171, macrogol 4000, talc E553b and indigo carmine aluminium lake E132).
Levetiracetam500mg Tablets – opadry® II yellow 85F32004 (polyvinyl alcohol-part. hydrolysed, titanium dioxide E171, macrogol 4000, talc E553b and iron oxide yellow E172).
Levetiracetam750mg Tablets – opadry® II orange 85F23452 (polyvinyl alcohol-part. hydrolysed, titanium dioxide E171, macrogol 4000, talc E553b, sunset yellow FCF aluminium lake E110 and iron oxide red E172).
Levetiracetam1,000mg Tablets – opadry® II white 85F18422 (polyvinyl alcohol-part. hydrolysed, titanium dioxide E171, macrogol 4000 and talc E553b).
What Levetiracetam Tablets look like and contents of the pack
Levetiracetam250mg Tablets are blue, film-coated, oval shaped, debossed with “W532” on one side and a score line on the other side.
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
Levetiracetam500mg Tablets are yellow, film-coated, oval shaped, debossed with “W53 3” on one side and a score line on the other side.
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
Levetiracetam750mg Tablets are orange, film-coated, oval shaped, debossed with “W53 4” on one side and a score line on the other side.
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
Levetiracetam1,000mg Tablets are white, film-coated, oval shaped, debossed with “W535” on one side and a score line on the other side.
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
Levetiracetam Tablets are supplied in a blister pack of 60 tablets within an outer carton.
Marketing Authorisation Holder: SNIGD (UK Limited), Office Gold, Building 3 Chiswick Park, 566 Chiswick High Road, London, England, W4 5YA
Manufacturer: CP Pharmaceuticals Ltd, Ash Road North, Wrexham LL13 9UF, UK.
Other formats: To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge: 0800 198 5000 (UK Only).
Please be ready to give the following information:
| Product name | Reference number |
| Levetiracetam 250mg Film-Coated Tablets | PL 55539/0019 |
| Levetiracetam 500mg Film-Coated Tablets | PL 55539/0020 |
| Levetiracetam 750mg Film-Coated Tablets | PL 55539/0021 |
| Levetiracetam 1,000mg Film-Coated Tablets | PL 55539/0018 |
This is a service provided by the Royal National Institute of Blind People.
These medicinal products are authorised in the Member States of the EEA under the following names:
UK: Levetiracetam 250mg, 500mg, 750mg or 1,000mg Film-Coated Tablets Malta:
Levetiracetam Wockhardt 250mg, 500mg, 750mg or 1,000mg Film-Coated Tablets
This leaflet was last revised in October 2021